Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.

Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated wit...

Full description

Bibliographic Details
Main Authors: Elena G Kamburova, Hans J P M Koenen, Martijn W F van den Hoogen, Marije C Baas, Irma Joosten, Luuk B Hilbrands
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4231065?pdf=render
id doaj-804f77fa801a49138c380ea6cd75f0ba
record_format Article
spelling doaj-804f77fa801a49138c380ea6cd75f0ba2020-11-25T02:47:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e11265810.1371/journal.pone.0112658Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.Elena G KamburovaHans J P M KoenenMartijn W F van den HoogenMarije C BaasIrma JoostenLuuk B HilbrandsPrevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated with tacrolimus, mycophenolate mofetil (MMF), steroids, and a single dose of rituximab or placebo during transplant surgery. In a subset of patients, we analyzed the number and phenotype of peripheral T and B cells by multiparameter flow cytometry before transplantation, and at 3, 6, 12, and 24 months after transplantation.In patients treated with tacrolimus/MMF/steroids the proportion of central memory CD4+ and CD8+ T cells was higher at 3 months post-transplant compared to pre-transplant levels. In addition, the ratio between the percentage of central memory CD4+ and CD4+ regulatory T cells was significantly higher up to 24 months post-transplant compared to pre-transplant levels. Interestingly, treatment with tacrolimus/MMF/steroids resulted in a shift toward a more memory-like B-cell phenotype post-transplant. Addition of a single dose of rituximab resulted in a long-lasting B-cell depletion. At 12 months post-transplant, the small fraction of repopulated B cells consisted of a high percentage of transitional B cells. Rituximab treatment had no effect on the T-cell phenotype and function post-transplant.Renal transplant recipients treated with tacrolimus/MMF/steroids show an altered memory T and B-cell compartment post-transplant. Additional B-cell depletion by rituximab leads to a relative increase of transitional and memory-like B cells, without affecting T-cell phenotype and function.ClinicalTrials.gov NCT00565331.http://europepmc.org/articles/PMC4231065?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Elena G Kamburova
Hans J P M Koenen
Martijn W F van den Hoogen
Marije C Baas
Irma Joosten
Luuk B Hilbrands
spellingShingle Elena G Kamburova
Hans J P M Koenen
Martijn W F van den Hoogen
Marije C Baas
Irma Joosten
Luuk B Hilbrands
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
PLoS ONE
author_facet Elena G Kamburova
Hans J P M Koenen
Martijn W F van den Hoogen
Marije C Baas
Irma Joosten
Luuk B Hilbrands
author_sort Elena G Kamburova
title Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
title_short Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
title_full Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
title_fullStr Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
title_full_unstemmed Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
title_sort longitudinal analysis of t and b cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated with tacrolimus, mycophenolate mofetil (MMF), steroids, and a single dose of rituximab or placebo during transplant surgery. In a subset of patients, we analyzed the number and phenotype of peripheral T and B cells by multiparameter flow cytometry before transplantation, and at 3, 6, 12, and 24 months after transplantation.In patients treated with tacrolimus/MMF/steroids the proportion of central memory CD4+ and CD8+ T cells was higher at 3 months post-transplant compared to pre-transplant levels. In addition, the ratio between the percentage of central memory CD4+ and CD4+ regulatory T cells was significantly higher up to 24 months post-transplant compared to pre-transplant levels. Interestingly, treatment with tacrolimus/MMF/steroids resulted in a shift toward a more memory-like B-cell phenotype post-transplant. Addition of a single dose of rituximab resulted in a long-lasting B-cell depletion. At 12 months post-transplant, the small fraction of repopulated B cells consisted of a high percentage of transitional B cells. Rituximab treatment had no effect on the T-cell phenotype and function post-transplant.Renal transplant recipients treated with tacrolimus/MMF/steroids show an altered memory T and B-cell compartment post-transplant. Additional B-cell depletion by rituximab leads to a relative increase of transitional and memory-like B cells, without affecting T-cell phenotype and function.ClinicalTrials.gov NCT00565331.
url http://europepmc.org/articles/PMC4231065?pdf=render
work_keys_str_mv AT elenagkamburova longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
AT hansjpmkoenen longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
AT martijnwfvandenhoogen longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
AT marijecbaas longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
AT irmajoosten longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
AT luukbhilbrands longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy
_version_ 1724754904510103552